At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 25 enrolled
Drug / intervention
Flutamide +1 moredrug
Likely dose
Flutamide 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Apr 25, 2018·Updated Oct 16, 2025
In Brief
A Early Phase 1 clinical trial evaluating Flutamide and Placebo for Prostate Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This is a prospective, single-center, two-phase study to assess the efficacy of single pulsed-dose flutamide in creating double strand breaks (DSBs) in prostate cancer within patients receiving central androgen suppression and brachytherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsPatrick C. Walsh Fund
Timeline
Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2019
Primary CompletionSep 2024
Study CompletionJul 2025
TodayJul 2026
First PostedApr 25, 2018
Enrollment StartMay 10, 2019
Primary CompletionSep 30, 2024
Study CompletionJul 3, 2025
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 8.2 years ago
Interventions
Flutamidedrug
50mg flutamide prior to brachytherapy and prostatic biopsy
Placeboother
placebo prior to brachytherapy and prostatic biopsy